NEW YORK (GenomeWeb News) – Pacific Biosciences announced that Michael Hunkapiller is replacing Hugh Martin as the company's president and CEO, effective immediately. For more see today's article on GenomeWeb Daily News.
Illumina has appointed Marc Stapley to senior vice president and chief financial officer. Christian Henry, who had been serving dual positions as both the company's chief financial officer and general manager of Illumina's genetic analysis business, will continue to head the genetic analysis business. The change will go into effect on Jan. 20.
Stapley joins Illumina from Pfizer, where he served as senior vice president responsible for global financial processes and systems. Previously, he held various senior finance roles at Alcatel-Lucent. He also worked as finance director and controller for several groups at Cadence Design Systems.
DNA sequencing technology company Nabsys has appointed Stan Rose to take on the role of chief commercial officer, and it has named Jeffrey Sklar to serve on its scientific advisory board. Rose formerly was CEO of NimbleGen Systems, he co-founded Genetic MicroSystems, and he directed Perkin-Elmer's and Applied Biosystems' PCR businesses. Sklar is director of the Molecular Diagnostics Program, the Molecular Tumor Profiling Laboratory, and the Molecular Genetics Pathology Fellowship at Yale University School of Medicine.
Michael Marletta this week assumed the job of president and CEO of the Scripps Research Institute, a post he has taken over from Richard Lerner, who after 25 years leading the institute will continue to work there as a researcher. Marletta, whose appointment to the position was announced in early 2011, formerly was chair of the Department of Chemistry and a professor in the Department of Molecular and Cell Biology at The University of California, Berkeley.
PrimeraDx said this week that David Jackson has been appointed as vice president of business development. Jackson most recently was employed at Qiagen, where he served as a member of the companion diagnostics partnerships team in global business development. Prior to that, he held a similar VP role with DxS, which was acquired by Qiagen in 2009.
Pressure Biosciences said this week in a statement to the US Securities and Exchange Commission that its shareholders have re-elected Richard Schumacher, Alan Goldberg, and Gregory Freitag to its board of directors.
NeoGenomics has appointed Barbara Chaitin to be director of surgical pathology for NeoGenomics Laboratories and medical director of its lab in Fort Myers, Fla.
Chaitin recently was at the AmeriPath division of Quest Diagnostics, where she was director of esoteric services and chair of the Solid Tumor Committee. She also was national medical director and head of solid tumor services at Genzyme Genetics and associate medical director at Impath Laboratories in New York City.
Vermillion said this week in an SEC filing that Ashish Kohli has resigned his post as VP of corporate strategy effective Feb. 29 The firm also said that it will eliminate that position and the CFO position as well. It also reduced the number of authorized directors to seven from eight, eliminating a vacant seat on its board.
Predictive Biosciences has appointed Angelo De Marzo as chief medical officer. De Marzo previously was a faculty member at The Johns Hopkins University School of Medicine, where he was a professor of pathology, urology, and oncology, director of the Pathology Core for Specialized Cancer Research in prostate cancer. Also at Johns Hopkins, De Marzo was associate director of Pathology Cancer Research at the Sidney Kimmel Comprehensive Cancer Center and director of the Tissue Microarray Core Facility.
WaferGen BioSystems stated in an SEC filing this week that it has re-elected six members to its board of directors including Alnoor Shivji; Robert Coradini; Dean Hautamaki; Mokoto Kaneshiro; Joel Kanter; and Timothy Triche.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.